Acumen Pharmaceuticals Inc

ABOS

Company Profile

  • Business description

    Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

  • Contact

    1210-1220 Washington Street
    Suite 210
    NewtonMA02465
    USA

    T: +1 617 344-4190

    https://www.acumenpharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,833.604.900.06%
CAC 407,753.2414.820.19%
DAX 4023,881.9391.820.39%
Dow JONES (US)44,484.4210.52-0.02%
FTSE 1008,824.3149.620.57%
HKSE24,069.94151.47-0.63%
NASDAQ20,393.13190.240.94%
Nikkei 22539,785.9023.420.06%
NZX 50 Index12,704.4879.81-0.62%
S&P 5006,227.420.000.00%
S&P/ASX 2008,595.801.90-0.02%
SSE Composite Index3,461.156.360.18%

Market Movers